stockrow
Friday 6 November 2026
Export NPCE’s income statement to Excel — free account
NeuroPace, Inc.
NPCE Healthcare Medical Devices
NeuroPace, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $100.0 million, up 25.1% from fiscal 2024.
- Revenue
- −2.95%
- EPS
- +30.8%
- Free cash flow
- −78.7%
- Total debt
- +0.68%
Quarter to June 2026, against a year earlier
12.47
0.22
−1.73%
Follow NPCE
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
3.60 | 5.05 | 4.45 | 5.48 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(175.73) | 998.49 | (75.15) | (138.85) | |
P/B ratio |
18.45 | 26.55 | 30.68 | 45.60 | |
Price to Tangible BV |
18.45 | 26.55 | 30.68 | 45.60 | |
EV/Sales |
3.63 | 5.07 | 4.54 | 5.59 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(21.09) | (46.03) | (47.96) | (49.18) | |
EV/FCF |
(20.74) | (44.69) | (45.95) | (47.62) | |
Quick Ratio |
3.82 | 4.15 | 4.25 | 3.82 | |
Current Ratio |
4.86 | 5.28 | 5.38 | 4.94 | |
Net Debt/EBITDA |
0.38 | (1.50) | (1.01) | (1.61) | |
Debt/Assets |
54.77% | 55.78% | 59.68% | 60.84% | |
Debt/Equity |
3.17 | 3.09 | 4.08 | 4.97 | |
Asset Turnover |
0.93 | 1.00 | 0.95 | 0.97 | |
Operating CF/Net income |
0.56 | (0.19) | 0.88 | 0.63 | |
Capex/Depreciation |
0.04 | (0.05) | (0.20) | (0.21) | |
Interest Coverage |
(1.58) | (0.25) | (3.66) | (3.34) | |
Research and Development Expense of Revenue |
24.04% | 26.43% | 32.58% | 30.22% | |
Selling, General and Administrative Expense of Revenue |
62.85% | 59.70% | 74.44% | 75.14% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
9.61% | 9.81% | 10.32% | 10.09% | |
Graham Net Nets |
0.02 | 0.01 | 0.01 | 0.00 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(7.37%) | (4.27%) | (4.94%) | (3.59%) | |
Free Cash Flow Yield |
(4.85%) | (2.24%) | (2.22%) | (2.14%) | |
Revenue per Share |
0.83 | 0.81 | 0.65 | 0.67 | |
Operating CF per Share |
(0.06) | 0.02 | (0.17) | (0.11) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.06) | 0.01 | (0.18) | (0.12) | |
Cash per Share |
1.81 | 1.87 | 1.60 | 1.52 | |
Shareholders Equity per Share |
0.56 | 0.58 | 0.43 | 0.35 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.56 | 0.58 | 0.43 | 0.35 | |
Free Cash Flow |
(1.97) | 0.41 | (6.02) | (4.03) | |
Working Capital |
75.72 | 76.26 | 70.81 | 68.76 | |
Capital Expenditures |
(0.03) | (0.10) | (0.12) | (0.12) | |
Net Current Asset Value |
6.59 | 7.54 | 2.53 | 1.09 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.01 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
13.25 | 12.89 | 15.11 | 14.24 | |
Average Payables |
3.38 | 2.37 | 4.28 | 4.46 | |
Average Inventory |
15.11 | 14.12 | 15.14 | 17.23 | |
Average Assets |
101.78 | 100.11 | 104.55 | 101.55 | |
Average Common Equity |
14.17 | 13.52 | 19.36 | 15.66 |
Columns are period end dates · fundamentals updated 26 Oct 2026